Contemporary strategies to improve outcomes for peripheral T-cell lymphoma patients following the failure of first-line therapy

References

• A clinical evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin’s Lymphoma. The non-Hodgkin’s lymphoma classification project. Blood. 1997;89(11):3909–3918.
   PubMed Web of Science ®Google Scholar
• Whang‐Peng J, Knutsen T, Bunn PA Jr, et al. Clinical implications of cytogenetic studies in cutaneous T‐cell lymphoma (CTCL). Cancer. 1982;50(8):1539–1553.
   PubMed Web of Science ®Google Scholar
• Pinkus GS, Said JW, Hargreaves H. Malignant lymphoma, T-cell type: A distinct morphologic variant with large multilobated nuclei, with a report of four cases. Am J Clin Pathol. 1979;72(4):540–550.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer; 2017. World health Organisation(2017).
   Google Scholar
• Wang SS, Vose JM. Epidemiology and prognosis of T-cell lymphoma. In: T-cell lymphomas. Humana Press, Totowa. 2013. p. 25–39.
   Google Scholar
• SEER database. SEER cancer stat. 2019;2020(January 2).
   Google Scholar
• Siaghani PJ, Wong JT, Chan J, et al. Epidemiology and pathology of T-and NK-cell lymphomas. In: T-cell and NK-cell lymphomas. Springer; Cham. 2019. p. 1–29.
   Google Scholar
• Zhang Y, Xu W, Liu H, et al. Therapeutic options in peripheral T cell lymphoma. J Hematol Oncol. 2016;9(1):37.
   PubMedGoogle Scholar
• Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood. 1998;92(1):76–82.
   PubMed Web of Science ®Google Scholar
• Savage K, Chhanabhai M, Gascoyne R, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467–1475.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the german high-grade non-hodgkin lymphoma study group. Blood. 2010;116(18):3418–3425.
   PubMed Web of Science ®Google Scholar
• Horwitz S, O’Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–240.
   PubMed Web of Science ®Google Scholar
• d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J clin oncol. 2012;30(25):3093–3099.
   PubMed Web of Science ®Google Scholar
• Lunning MA. Treatment of peripheral T-cell lymphoma: many shades of gray. Oncology. 2015;29(8). Available from: http://www.cancernetwork.com
   PubMed Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71(1):117–122.
   PubMed Web of Science ®Google Scholar
• Zelenetz A, Hamlin P, Kewalramani T, et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14(suppl_1):i5–i10.
   PubMedGoogle Scholar
• Emmanouilides C, Colovos C, Pinter-Brown L, et al. Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma. 2004;5(1):45–49.
   PubMedGoogle Scholar
• Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J clin oncol. 2013;31(16):1970–1976.
   PubMed Web of Science ®Google Scholar
• Stuver RN, Khan N, Schwartz M, et al. Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry. Am J Hematol. 2019;94(6):641–649.
   PubMed Web of Science ®Google Scholar
• Zinzani P, Magagnoli M, Bendandi M, et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol. 1998;9(12):1351–1353.
   PubMed Web of Science ®Google Scholar
• Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J clin oncol. 2012;31(1):104–110.
   PubMed Web of Science ®Google Scholar
• Ma H, Cheng B, Falchi L, et al. Survival benefit in patients with peripheral T‐cell lymphomas after treatments with novel therapies and clinical trials. Hematol. Oncol. 2019;37:472–473.
   Google Scholar
• O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182–1189.
   PubMed Web of Science ®Google Scholar
• Hong JY, Yoon DH, Yoon SE, et al. Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. Sci Rep. 2019;9(1):1–7.
   PubMedGoogle Scholar
• Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–5834.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J clin oncol. 2012;30(6):631–636.
   PubMed Web of Science ®Google Scholar
• Foss F, Advani R, Duvic M, et al. A phase II trial of belinostat (PXD 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma. Br J Haematol. 2015;168(6):811–819.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492–2499.
   PubMed Web of Science ®Google Scholar
• Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766–1771.
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–1465.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–2196.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–3100.
   PubMed Web of Science ®Google Scholar
• Weidmann E, Hess G, Chow KU, et al. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma. 2010;51(3):447–455.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Alinari L, Tani M, et al. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica. 2005;90(5):702–703.
   PubMed Web of Science ®Google Scholar
• Couronné L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366(1):95–96.
   PubMed Web of Science ®Google Scholar
• Lemonnier F, Dupuis J, Sujobert P, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood J Am Soc Hematol. 2018;132(21):2305–2309.
   Google Scholar
• Morschhauser F, Fitoussi O, Haioun C, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013;49(13):2869–2876.
   PubMed Web of Science ®Google Scholar
• Hopfinger G, Nösslinger T, Lang A, et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Ann Hematol. 2014;93(3):459–462.
   PubMed Web of Science ®Google Scholar
• William BM, Huang Y, Johnson A, et al. No title. Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial; 2019.
   Google Scholar
• Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888–898.
   PubMed Web of Science ®Google Scholar
• Iyer SP, Haverkos BM, Zain J, et al. No title. Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma; 2019.
   Google Scholar
• Oki Y, Zain J, Haverkos BM, et al. No title. Safety and Anti-Tumour Activity of RP6530, Dual PI3K δ/γ Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I/Ib Study; 2017.
   Google Scholar
• Feldman AL, Sun D, Law M, et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia. 2008;22(6):1139.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Feldman TA, Hess BT, et al. No title. The novel SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed/refractory peripheral T-Cell lymphoma and cutaneous T-cell lymphoma; 2018.
   Google Scholar
• Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J clin oncol. 2014;32(11):1157–1163.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Coiffier B, Radford J, et al. No title. A phase II open-label, multi-center study of anti-CCR4 monoclonal antibody mogamulizumab (KW-0761) in patients with previously treated peripheral T-cell lymphoma (PTCL); 2014.
   Google Scholar
• Manfredi MG, Ecsedy JA, Chakravarty A, et al. Characterization of alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res. 2011;17(24):7614–7624.
   PubMed Web of Science ®Google Scholar
• Barr PM, Li H, Spier C, et al. Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. J Clin Oncol. 2015;33(21):2399–2404.
   PubMed Web of Science ®Google Scholar
• Makita S, Maeshima AM, Maruyama D, et al. K. Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review. Onco Targets Ther. 2018;11:2287–2293.
   PubMed Web of Science ®Google Scholar
• Maruyama D, Tsukasaki K, Uchida T, et al. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma. Ann Hematol. 2019;98(1):131–142.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–2704.
   PubMed Web of Science ®Google Scholar
• Barta SK, Zain J, MacFarlane AW IV, et al. Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma. Clin Lymphoma Myeloma Leukemia. 2019;19(6):356–364.e3.
   PubMed Web of Science ®Google Scholar
• Maciocia P, Wawrzyniecka P, Philip B, et al. Targeting the t‐cell receptor β‐constant domain for immunotherapy of T‐cell malignancies. Hematol Oncol. 2017;35:252–253.
   PubMedGoogle Scholar
• Jain S, Jirau-Serrano X, Zullo KM, et al. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Clin Cancer Res. 2015;21(9):2096–2106.
   PubMed Web of Science ®Google Scholar
• Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018;131(4):397–407.
   PubMed Web of Science ®Google Scholar
• Marchi E, Zullo KM, Amengual JE, et al. The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T‐cell lymphoma. Br J Haematol. 2015;171(2):215–226.
   PubMed Web of Science ®Google Scholar
• Falchi L, Lue JK, Amengual JE, et al. A phase 1/2 study of oral 5-azacitidine and romidepsin in patients with lymphoid malignancies reveals promising activity in heavily pretreated peripheral T-cell lymphoma (PTCL); 2017.
   Google Scholar
• Park J, Jong H, Kim SG, et al. Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. J Mol Med. 2008;86(1):117–128.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Koch R, Mehta-Shah N, et al. In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ, γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma; 2017.
   Google Scholar
• Lunning MA, Horwitz S. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data? Curr Treat Options Oncol. 2013;14(2):212–223.
   PubMed Web of Science ®Google Scholar
• Beitinjaneh A, Saliba RM, Medeiros LJ, et al. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015;21(5):855–859.
   PubMed Web of Science ®Google Scholar
• Goldberg JD, Chou JF, Horwitz S, et al. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2012;53(6):1124–1129.
   PubMed Web of Science ®Google Scholar
• Paturel C, Chance F, Sicard F, et al. Anti-lymphoma activity of lacutamab(IPH4102), first in class anti- KIR3DL2 antibody, is augmented by PTCL chemotherapies. Innate Pharma, 117 Av de Lumity. Abstract presented at the T cell lymphoma forum, San francisco; 2020.
   Google Scholar